Concerns About Eye Toxicity Could Limit GSK’s Myeloma Drug Potential

US FDA Flags Safety Ahead Of Meeting

Company told more measures needed to limit damage to patients' eyes caused by antibody drug conjugate.

GSK_HQ
2020 marks GSK's return to the oncology field, including the highly competitive multiple myeloma market

More from Business

More from Scrip